Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin

Molecular mechanistic pathways underlying the anticancer therapeutic efficiency of romidepsin

Romidepsin, also known as NSC630176, FR901228, FK-228, FR-901228, depsipeptide, or Istodax®, is a natural molecule produced by the Chromobacterium violaceum bacterium that has been approved for its anti-cancer effect. This compound is a selective histone deacetylase (HDAC) inhibitor, which modifies...

Full description

Bibliographic Details
Main Authors:	Nasreddine El Omari, Learn-Han Lee, Saad Bakrim, Hafiz A. Makeen, Hassan A. Alhazmi, Syam Mohan, Asaad Khalid, Long Chiau Ming, Abdelhakim Bouyahya
Format:	Article
Language:	English
Published:	Elsevier 2023-08-01
Series:	Biomedicine & Pharmacotherapy
Subjects:	Romidepsin Tumour P53 Histone deacetylase inhibitors (HDACi) Molecular pathways Epigenetic
Online Access:	http://www.sciencedirect.com/science/article/pii/S0753332223005632

Similar Items

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
by: Guang Lu, et al.
Published: (2023-08-01)

Romidepsin controls chronic lymphocytic leukemia in a patient with mycosis fungoides
by: David M. Lemchak, et al.
Published: (2016-11-01)

HDAC Screening Identifies the HDAC Class I Inhibitor Romidepsin as a Promising Epigenetic Drug for Biliary Tract Cancer
by: Christian Mayr, et al.
Published: (2021-07-01)

Anticancer clinical efficiency and stochastic mechanisms of belinostat
by: Nasreddine El Omari, et al.
Published: (2023-09-01)

Molecular mechanisms underlying the clinical efficacy of panobinostat involve Stochasticity of epigenetic signaling, sensitization to anticancer drugs, and induction of cellular cell death related to cellular stresses
by: Nasreddine El Omari, et al.
Published: (2023-08-01)

The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus
by: Saikat Dewanjee, et al.
Published: (2021-05-01)

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
by: Nikolaos Garmpis, et al.
Published: (2021-03-01)

HAT- and HDAC-Targeted Protein Acetylation in the Occurrence and Treatment of Epilepsy
by: Jie Wang, et al.
Published: (2022-12-01)

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
by: Anton Frühauf, et al.
Published: (2021-08-01)

Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
by: Laura Gleason, et al.
Published: (2022-12-01)

HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models
by: María Del Carmen Rodríguez Rodríguez, et al.
Published: (2022-05-01)

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
by: Francine Foss, et al.
Published: (2016-03-01)

The Impact of Fluorination on the Design of Histone Deacetylase Inhibitors
by: Duong Tien Anh, et al.
Published: (2023-02-01)

Expression of Adenoviral E1A in Transformed Cells as an Additional Factor of HDACi-Dependent FoxO Regulation
by: Alisa Morshneva, et al.
Published: (2019-12-01)

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients
by: Cinzia Pellegrini, et al.
Published: (2016-04-01)

The epigenetic factor CHD4 contributes to metastasis by regulating the EZH2/β-catenin axis and acts as a therapeutic target in ovarian cancer
by: Jieyu Wang, et al.
Published: (2023-01-01)

Epigenetic Regulation of TRAIL Signaling: Implication for Cancer Therapy
by: Mohammed I. Y. Elmallah, et al.
Published: (2019-06-01)

Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy
by: Flávia Alves Verza, et al.
Published: (2020-06-01)

Current treatment strategies targeting histone deacetylase inhibitors in acute lymphocytic leukemia: a systematic review
by: Yingjun Zhang, et al.
Published: (2024-02-01)

HDAC Inhibitor Sodium Butyrate Attenuates the DNA Repair in Transformed but Not in Normal Fibroblasts
by: Olga O. Gnedina, et al.
Published: (2022-03-01)

CN133, a Novel Brain-Penetrating Histone Deacetylase Inhibitor, Hampers Tumor Growth in Patient-Derived Pediatric Posterior Fossa Ependymoma Models
by: Roberta Antonelli, et al.
Published: (2020-07-01)

Synergistic Effect of Simultaneous versus Sequential Combined Treatment of Histone Deacetylase Inhibitor Valproic Acid with Etoposide on Melanoma Cells
by: Yueh-Ming Shyu, et al.
Published: (2021-09-01)

Romidepsin Enhances the Killing Ability of NKG2D-CAR-T Cells through Enhanced Expression of NKG2DL against Ovarian Cancer Cells
by: Liang Wang, et al.
Published: (2022-09-01)

Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
by: Robert Jenke, et al.
Published: (2021-02-01)

Preclinical Studies in the mdx Mouse Model of Duchenne Muscular Dystrophy with the Histone Deacetylase Inhibitor Givinostat
by: Silvia Consalvi, et al.
Published: (2013-03-01)

Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy
by: Maria Mrakovcic, et al.
Published: (2019-12-01)

Natural Bioactive Compounds Targeting Histone Deacetylases in Human Cancers: Recent Updates
by: Abdelhakim Bouyahya, et al.
Published: (2022-04-01)

Dysregulation of Histone Deacetylases Inhibits Trophoblast Growth during Early Placental Development Partially through TFEB-Dependent Autophagy-Lysosomal Pathway
by: Peixin Wang, et al.
Published: (2023-07-01)

Harnessing Epigenetics for Breast Cancer Therapy: The Role of DNA Methylation, Histone Modifications, and MicroRNA
by: Joanna Szczepanek, et al.
Published: (2023-04-01)

Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma
by: Alyssa Noll, et al.
Published: (2023-09-01)

The Role of HDACs as Leukemia Therapy Targets using HDI
by: Ahmad Ahmadzadeh, et al.
Published: (2016-02-01)

Inactivation of Invs/Nphp2 in renal epithelial cells drives infantile nephronophthisis like phenotypes in mouse
by: Yuanyuan Li, et al.
Published: (2023-03-01)

Advanced Progress of Histone Deacetylases in Rheumatic Diseases
by: Liu XM, et al.
Published: (2024-02-01)

Insights into the Role of the Microbiota and of Short-Chain Fatty Acids in Rubinstein–Taybi Syndrome
by: Elisabetta Di Fede, et al.
Published: (2021-03-01)

Defining a Correlative Transcriptional Signature Associated with Bulk Histone H3 Acetylation Levels in Adult Glioblastomas
by: Irati Hervás-Corpión, et al.
Published: (2023-01-01)

Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
by: Wai C. Chong, et al.
Published: (2021-10-01)

The Roles of Histone Deacetylases in the Regulation of Ovarian Cancer Metastasis
by: Long Xu, et al.
Published: (2023-10-01)

Histone Deacetylases and Their Isoform-Specific Inhibitors in Ischemic Stroke
by: Svetlana Demyanenko, et al.
Published: (2021-10-01)

Histone Deacetylase Functions in Gastric Cancer: Therapeutic Target?
by: Amandine Badie, et al.
Published: (2022-11-01)

Histone Deacetylase Expressions in Hepatocellular Carcinoma and Functional Effects of Histone Deacetylase Inhibitors on Liver Cancer Cells In Vitro
by: Kim Freese, et al.
Published: (2019-10-01)